Rentschler Biopharma launches gene therapy subsidiary
CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2151 entries already.
Entries by Thomas Gabrielczyk
InteRNA Technologies secures €18.5m in Series B financing
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
German Health Ministry to invest €6.2bn in vaccines
The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures launches second fund at €78m
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise €35m in Series A extension
Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.
German antibodies in demand in USA
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Omnix Medical bags €10.8m from EIC Accerator Fund
Israel’s Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.